Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic

Among the army of biotechs that threw themselves into the gold rush for 2019-nCoV vaccines or therapies, Moderna emerged as one of the most legitimate contenders: The NIH had signed it on as a partner, demonstrating confidence in its messenger RNA platform to produce a vaccine rapidly.